PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented a poster on ARC-HIF2, its preclinical development program targeting HIF2-α for the treatment of renal cell carcinoma (RCC), at the American Association for Cancer Research Annual Meeting 2016 (AACR16), in New Orleans. ARC-HIF2 is Arrowhead’s first RNAi therapeutic program to target tissues outside the liver.
The poster titled, “Novel HIF-2α targeted RNAi therapeutic for renal cell carcinoma” (abstract 2064), describes data from various stages of development of ARC-HIF2, including RNAi trigger selection, HIF2-α target validation, delivery and targeting ligand validation, and multiple RCC tumor models. These data show that important advancements are being made in this program and for Arrowhead’s Dynamic PolyconjugateTM (DPCTM) delivery platform generally, including the following key findings:
- Proof-of-concept ligand dependent, functional delivery was demonstrated using the DPC targeted delivery platform
- Silencing HIF2-α expression by RNA interference resulted in reduction of HIF-2α regulated genes
- In two different RCC tumor bearing mouse models, ARC-HIF2 inhibited tumor growth and promoted tumor cell death and structural degeneration
A copy of the poster presentation is available on the Events and Presentations page under the Investors section of the Arrowhead website.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals
develops medicines that treat intractable diseases by silencing the
genes that cause them. Using a broad portfolio of RNA chemistries and
efficient modes of delivery, Arrowhead therapies trigger the RNA
interference mechanism to induce rapid, deep, and durable knockdown of
target genes. RNA interference, or RNAi, is a mechanism present in
living cells that inhibits the expression of a specific gene, thereby
affecting the production of a specific protein. Arrowhead’s RNAi-based
therapeutics leverage this natural pathway of gene silencing. The
company’s pipeline includes ARC-520 and ARC-521 for chronic hepatitis B
virus, ARC-AAT for liver disease associated with alpha-1 antitrypsin
deficiency, ARC-F12 for hereditary angioedema and thromboembolic
disorders, ARC-LPA for cardiovascular disease, and ARC-HIF2 for renal
cell carcinoma.
For more information please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation Reform
Act:
This news release contains forward-looking statements
within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are based
upon our current expectations and speak only as of the date hereof. Our
actual results may differ materially and adversely from those expressed
in any forward-looking statements as a result of various factors and
uncertainties, including our ability to finance our operations, the
future success of our scientific studies, our ability to successfully
develop drug candidates, the timing for starting and completing clinical
trials, rapid technological change in our markets, and the enforcement
of our intellectual property rights. Our most recent Annual Report on
Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of
the important risk factors that may affect our business, results of
operations and financial condition. We assume no obligation to update or
revise forward-looking statements to reflect new events or circumstances.
DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Pharmaceuticals, Inc.
Source: Arrowhead Pharmaceuticals, Inc.
